New pill CMS-D017 enters first human safety trials

NCT ID NCT07462780

Recruiting now Knowledge-focused Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CMS-D017 capsule
What this could lead to: If safe, this could lead to further studies testing CMS-D017 as a treatment for paroxysmal nocturnal hemoglobinuria and complement-mediated kidney disease.
What could go wrong: This is an early Phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLEMENT-MEDIATED KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

C3 glomerulonephritis complement 3 glomerulopathy Hemoglobinuria, Paroxysmal paroxysmal nocturnal hemoglobinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMPLEMENT-MEDIATED KIDNEY DISEASE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH

Contacts and locations

Locations

Peking University Third Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.